JP2010534242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534242A5 JP2010534242A5 JP2010518228A JP2010518228A JP2010534242A5 JP 2010534242 A5 JP2010534242 A5 JP 2010534242A5 JP 2010518228 A JP2010518228 A JP 2010518228A JP 2010518228 A JP2010518228 A JP 2010518228A JP 2010534242 A5 JP2010534242 A5 JP 2010534242A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- agent
- disease
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 claims description 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 2
- 229940124135 Factor VIII inhibitor Drugs 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 241000124008 Mammalia Species 0.000 description 5
- 230000001668 ameliorated effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96204407P | 2007-07-25 | 2007-07-25 | |
| PCT/US2008/009030 WO2009014744A1 (en) | 2007-07-25 | 2008-07-25 | Methods and compositions for treating autoimmune disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534242A JP2010534242A (ja) | 2010-11-04 |
| JP2010534242A5 true JP2010534242A5 (enExample) | 2012-07-26 |
Family
ID=39768887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518228A Pending JP2010534242A (ja) | 2007-07-25 | 2008-07-25 | 自己免疫疾患を治療するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8986684B2 (enExample) |
| EP (1) | EP2185593B1 (enExample) |
| JP (1) | JP2010534242A (enExample) |
| KR (1) | KR20100036362A (enExample) |
| AU (1) | AU2008279618B2 (enExample) |
| BR (1) | BRPI0814645A2 (enExample) |
| CA (1) | CA2694121C (enExample) |
| MX (1) | MX2010000979A (enExample) |
| WO (1) | WO2009014744A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534243A (ja) | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
| BR112012020101A2 (pt) | 2010-02-11 | 2018-09-25 | Alexion Pharma Inc | método diagnósticos e terapêuticos usando anticorpos anti-cd200. |
| US9447187B2 (en) | 2011-02-03 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
| US11299528B2 (en) * | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| AU2017248264B2 (en) | 2016-04-07 | 2020-01-30 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
| WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN111821251B (zh) * | 2020-07-07 | 2022-06-14 | 北京清大赛尔生物科技有限公司 | 化妆品用组合物和化妆品 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940475A (en) * | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| US4289747A (en) * | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE3307869A1 (de) | 1983-03-05 | 1984-09-06 | Dragoco Gerberding & Co Gmbh, 3450 Holzminden | Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe |
| ATE68703T1 (de) | 1984-02-08 | 1991-11-15 | Cetus Corp | Toxinkonjugate. |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3852304T3 (de) | 1987-03-02 | 1999-07-01 | Enzon Labs Inc., Piscataway, N.J. | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". |
| JPH0246297A (ja) | 1988-08-08 | 1990-02-15 | Takeda Chem Ind Ltd | モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2113940T3 (es) * | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| US5780279A (en) * | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| EP0606217B2 (en) * | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
| US5728815A (en) | 1992-03-30 | 1998-03-17 | Board Of Regents, The University Of Texas System | Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis |
| US5508717A (en) * | 1992-07-28 | 1996-04-16 | Sony Corporation | Computer pointing device with dynamic sensitivity |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| JP2000500438A (ja) * | 1995-10-31 | 2000-01-18 | ザ ユーエイビー リサーチ ファウンディシャン | 標的放射線治療用レセプタの遺伝子誘導 |
| WO1997021450A1 (en) * | 1995-12-08 | 1997-06-19 | Brigham And Women's Hospital, Inc. | Ox-2 costimulatory molecule |
| AU710998B2 (en) * | 1996-03-20 | 1999-10-07 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith |
| US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
| JP4584447B2 (ja) * | 1997-11-07 | 2010-11-24 | トリリアム・セラピューティクス・インコーポレイテッド | 免疫調節のための方法および組成物 |
| US6955811B2 (en) * | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020192215A1 (en) * | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
| US7291330B2 (en) * | 2000-03-17 | 2007-11-06 | Trillium Therapeutics Inc. | MD-1 inhibitors as immune suppressants |
| US7306801B2 (en) * | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| AU2001278338A1 (en) | 2000-08-03 | 2002-02-18 | David A Clark | Methods and compositions for modulating tumor growth |
| US20030017491A1 (en) * | 2000-09-14 | 2003-01-23 | Zuo-Rong Shi | Chromogenic in situ hybridization methods, kits, and compositions |
| EP1337560B8 (en) | 2000-11-22 | 2008-10-15 | Trillium Therapeutics Inc. | Truncated cd200 |
| ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7427665B2 (en) * | 2000-12-08 | 2008-09-23 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line |
| US7368535B2 (en) * | 2001-05-24 | 2008-05-06 | Trillium Therapeutics Inc. | CD200 receptors |
| ATE448320T1 (de) | 2001-09-19 | 2009-11-15 | Alexion Pharma Inc | Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| CA2511513A1 (en) * | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
| CA2517519A1 (en) | 2003-03-04 | 2004-09-16 | Alexion Pharmaceuticals, Inc. | Vectors used to create hybrid constant regions |
| JP2007501021A (ja) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| US20070148170A1 (en) * | 2005-10-03 | 2007-06-28 | Desjarlais John R | Fc Variants With Optimized Fc Receptor Binding Properties |
| US6953417B2 (en) * | 2003-11-17 | 2005-10-11 | Borgwarner Inc. | Method for controlling a dual clutch transmission |
| US20050169870A1 (en) * | 2004-02-02 | 2005-08-04 | Schering Corporation | Methods of modulating CD200 |
| US8815235B2 (en) * | 2004-06-02 | 2014-08-26 | Jan E. Schnitzer | Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| US20070036786A1 (en) * | 2005-07-11 | 2007-02-15 | Nadine Tuaillon | Method of treating autoimmune disease using humanized anti-CD16A antibodies |
| US8075884B2 (en) | 2006-01-12 | 2011-12-13 | Alexion Pharmaceuticals, Inc. | Antibodies to OX-2/CD200 and uses thereof |
| US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
-
2008
- 2008-07-25 US US12/452,772 patent/US8986684B2/en not_active Expired - Fee Related
- 2008-07-25 AU AU2008279618A patent/AU2008279618B2/en not_active Ceased
- 2008-07-25 WO PCT/US2008/009030 patent/WO2009014744A1/en not_active Ceased
- 2008-07-25 JP JP2010518228A patent/JP2010534242A/ja active Pending
- 2008-07-25 MX MX2010000979A patent/MX2010000979A/es not_active Application Discontinuation
- 2008-07-25 CA CA2694121A patent/CA2694121C/en not_active Expired - Fee Related
- 2008-07-25 KR KR1020107003120A patent/KR20100036362A/ko not_active Ceased
- 2008-07-25 BR BRPI0814645-4A2A patent/BRPI0814645A2/pt not_active IP Right Cessation
- 2008-07-25 EP EP08794739.6A patent/EP2185593B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2011520898A5 (enExample) | ||
| JP2016508984A5 (enExample) | ||
| JP2009540018A5 (enExample) | ||
| RU2011116181A (ru) | Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами | |
| JP2020517740A5 (enExample) | ||
| JP2020073504A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| JP2010512320A5 (enExample) | ||
| JP2010510323A5 (enExample) | ||
| RU2010132956A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| JP2017079785A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| JP2007527406A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| RU2017106804A (ru) | Анти-pd-l1 антитела | |
| WO2009140348A4 (en) | Anti-il-6/il-6r antibodies and methods of use thereof | |
| JP2019504032A5 (enExample) | ||
| JP2012522523A5 (enExample) | ||
| JP2009518005A5 (enExample) | ||
| JP2010527356A5 (enExample) | ||
| JP2009519718A5 (enExample) | ||
| JP2010526028A5 (enExample) |